The effects of β-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis

American Heart Journal

Volumn 154, Issue 3, 2007, Pages 589-595

  de Groote, Pascal ^a   Delour, Pierre ^a   Mouquet, Frédéric ^a   Lamblin, Nicolas ^a   Dagorn, Joël ^a   Hennebert, Olivier ^a   Le Tourneau, Thierry ^a   Foucher Hossein, Claude ^a   Verkindère, Christine ^a   Bauters, Christophe ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAMIPRIL; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOPULMONARY EXERCISE TEST; DRUG DOSE INCREASE; ECHOCARDIOGRAPHY; FEMALE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; PROGNOSIS; SCINTIANGIOGRAPHY;

EID: 34548102353     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.05.013     Document Type: Article

References (24)

1. CIBIS-II investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
2. MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353 (1999) 2001-2007
3. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
4. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (2005) e154-e235
5. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
6. Hall S.A., Cigarroa C.G., Marcoux L., et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 25 (1995) 1154-1161
7. Bristow M.R., O'Connell J.B., Gilbert E.M., et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation 89 (1994) 1632-1642
8. Lechat P., Packer M., Chalon S., et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-bind, placebo-controlled, randomized trials. Circulation 98 (1998) 1184-1191
9. Groenning B.A., Nilsson J.C., Sondergaard L., et al. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 36 (2000) 2072-2080
10. Packer M., Antonopoulos G.V., Berlin J.A., et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 141 (2001) 899-907
11. O'Keefe Jr. J.H., Magalski A., Stevens T.L., et al. Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure. J Nucl Cardiol 7 (2000) 3-7
12. Schleman K.A., Lindenfeld J.A., Lowes B.D., et al. Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. J Card Fail 7 (2001) 4-12
13. Bello D., Shah D.J., Farah G.M., et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 108 (2003) 1945-1953
14. Eichhorn E.J., Grayburn P.A., Mayer S.A., et al. Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with beta-blockade in patients with heart failure: the Beta-Blocker Evaluation of Survival Trial (BEST). Circulation 108 (2003) 2336-2341
15. Jourdain P., Funck F., Fulla Y., et al. Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol. Eur J Heart Fail 4 (2002) 269-276
16. Seghatol F.F., Shah D.J., Diluzio S., et al. Relation between contractile reserve and improvement in left ventricular function with beta-blocker therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 93 (2004) 854-859
17. Cleland J.G., Pennell D.J., Ray S.G., et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 362 (2003) 14-21
18. Lechat P., Escolano S., Golmard J.L., et al. Prognostic value of Bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 96 (1997) 2197-2205
19. Metra M., Nodari S., Parrinello G., et al. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J 145 (2003) 292-299
20. de Groote P., Millaire A., Foucher-Hossein C., et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol 32 (1998) 948-954
21. Lowes B.D., Gilbert E.M., Abraham W.T., et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346 (2002) 1357-1365
22. Ramahi T.M., Longo M.D., Cadariu A.R., et al. Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after beta-blocker therapy in nonischemic cardiomyopathy. J Am Coll Cardiol 37 (2001) 818-824
23. Kasama S., Toyama T., Hoshizaki H., et al. Dobutamine gated blood pool scintigraphy predicts the improvement of cardiac sympathetic nerve activity, cardiac function, and symptoms after treatment in patients with dilated cardiomyopathy. Chest 122 (2002) 542-548
24. Al-Ahmad A., Rand W.M., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 955-962